Full-Time
Posted on 7/4/2025
Develops and manufactures biopharmaceutical products
No salary listed
Senior
Visakhapatnam, Andhra Pradesh, India
In Person
Pfizer is a biopharmaceutical company that focuses on creating and producing healthcare products, including medicines and vaccines. The company conducts extensive research and development to discover new treatments, which are then manufactured and sold globally. Pfizer's products include vaccines, oncology treatments, and other specialized medicines, with a significant role in developing a vaccine for COVID-19 in partnership with BioNTech. What sets Pfizer apart from its competitors is its strong commitment to public health, demonstrated by efforts to provide vaccines to underserved populations and a continuous expansion of its product portfolio through new approvals. The goal of Pfizer is to improve health outcomes worldwide by delivering effective healthcare solutions.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Simpson Thacher represented the underwriters, led by Goldman Sachs & Co. LLC, BNP PARIBAS, HSBC, Mizuho, among others in connection with a registered offering of €3.3 billion in Notes by Pfizer, Inc.’s (“Pfizer”) wholly-owned subsidiary, Pfizer Netherlands International Finance B.V. (the “Issuer”). The Notes were issued in four series with maturities ranging from 2029 to 2045, with proceeds intended to be used for general corporate purposes. The Notes are fully and unconditionally guaranteed on a senior unsecured basis by Pfizer.
Trimtech Therapeutics, a Cambridge, UK-based biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, raised $31M in Seed funding
Normunity, a biotechnology company creating novel anti-cancer therapies, today announced that it has closed a Series B financing for $75 million. The
The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune diseases.
The drugmaker’s shares have slumped as demand for Covid-19 vaccines and treatments had slowed.